VOLUME 3, ISSUE 2, P176, JUNE 01, 2022
Manish Banker, M.S., Parul Arora, M.D., D.N.B., Jwal Banker, M.S., D.N.B., Reena Gupta, M.S., F.N.B., Sandeep Shah, M.S.
The authors thank Prof Ata and his associates for showing interest in our article entitled “Follicular phase cycle programming using estradiol in oocyte donors-a convenient and effective approach”(1). It is, indeed, rewarding to note that Turkgeldi et al. (2) have also studied cycle programming using estradiol in oocyte donors and have noted similar results as those of our study. Their results were first presented in the European Society of Human Reprodution and Embryology in 2019 (2) and subsequently published as a research article in April 2021 (3). Interestingly, our team of investigators had just finished the manuscript draft of our paper and submitted it to Fertility and Sterility on July 7, 2021. It was transferred to F&S Reports a month later. It is unfortunate that we missed citing the results of cycle programming of Turkgeldi et al. (2) in our article because we restricted our search to Pubmed. Their study was a retrospective analysis investigating the stimulation characteristics and ovarian response, that is, the numbers of cumulus oocyte complexes and metaphase II stage oocytes, whereas our study was a prospective study and followed up clinical and embryological results until the implantation rates and pregnancy rates. The rationale behind using estradiol for follicular phase cycle programming is similar to what Turkgeldi et al. (2) have proposed, and the results with estradiol have been promising so far. Further multicentric trials using estradiol for follicular phase cycle programming are needed that may validate its usage for a convenient cycle programming even in routine in vitro fertilization patients.